Business Context and Reporting Period
Oragenics, Inc. filed this Form 8-K on March 6, 2006, reporting the closing of a private placement transaction and the repayment of a bank loan. The company is incorporated in Florida and is headquartered in Alachua, Florida.
Key Financial Metrics and Transactions
- Capital Raised: $600,000 total proceeds from a private placement.
- Equity Issued: 1,500,000 shares of common stock at $0.40 per share.
- Warrants Issued: 1,500,000 warrants with an exercise price of $0.60 per share, exercisable for two years.
- Debt Repayment: The company voluntarily repaid all remaining principal and interest on its bank loan.
- Use of Proceeds: General corporate purposes.
The filing does not provide specific values for revenue, profit, cash flow, margins, or overall liquidity beyond the specific transaction details noted above.
Material Changes
The primary material change is the increase in equity capital and the elimination of the company's outstanding bank loan debt. The private placement was made to accredited investors who were existing shareholders, relying on the Section 4(2) exemption from registration.
Outlook, Risks, and Contingencies
- Registration Obligations: The company is obligated to file a registration statement with the SEC within 45 days to cover the resale of the newly issued shares and shares issuable upon warrant exercise.
- Warrant Call Provision: The warrants are callable by the company if the common stock trades at or above $1.60 per share for a consecutive 30-day period.
- Management Commentary: No specific forward-looking guidance or management commentary regarding future operations was included in this report.
Key Facts for Investor Verification
- Verify the filing of the required registration statement within the 45-day window following the January 6, 2006 agreement date.
- Confirm the full extinguishment of the bank loan debt as stated in the voluntary repayment.
- Monitor the stock price relative to the $1.60 threshold to assess the potential call of the issued warrants.
- Review the attached press release (Exhibit 99.1) for additional context on the private placement.